JP2012102122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012102122A5 JP2012102122A5 JP2011284589A JP2011284589A JP2012102122A5 JP 2012102122 A5 JP2012102122 A5 JP 2012102122A5 JP 2011284589 A JP2011284589 A JP 2011284589A JP 2011284589 A JP2011284589 A JP 2011284589A JP 2012102122 A5 JP2012102122 A5 JP 2012102122A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cancer
- polypeptide
- therapeutic agent
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57297304P | 2004-05-20 | 2004-05-20 | |
| US60/572,973 | 2004-05-20 | ||
| US63538004P | 2004-12-10 | 2004-12-10 | |
| US60/635,380 | 2004-12-10 | ||
| US67128105P | 2005-04-14 | 2005-04-14 | |
| US60/671,281 | 2005-04-14 | ||
| US68044705P | 2005-05-12 | 2005-05-12 | |
| US60/680,447 | 2005-05-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527588A Division JP4982373B2 (ja) | 2004-05-20 | 2005-05-20 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012102122A JP2012102122A (ja) | 2012-05-31 |
| JP2012102122A5 true JP2012102122A5 (enExample) | 2013-02-28 |
Family
ID=34971701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527588A Expired - Fee Related JP4982373B2 (ja) | 2004-05-20 | 2005-05-20 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
| JP2011284589A Ceased JP2012102122A (ja) | 2004-05-20 | 2011-12-27 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527588A Expired - Fee Related JP4982373B2 (ja) | 2004-05-20 | 2005-05-20 | Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US20050265966A1 (enExample) |
| EP (4) | EP2431050A1 (enExample) |
| JP (2) | JP4982373B2 (enExample) |
| KR (1) | KR101236177B1 (enExample) |
| CN (2) | CN103127502A (enExample) |
| AU (1) | AU2005245031B2 (enExample) |
| BR (1) | BRPI0511187A (enExample) |
| CA (1) | CA2566745A1 (enExample) |
| CY (1) | CY1113287T1 (enExample) |
| DK (1) | DK1758610T3 (enExample) |
| ES (1) | ES2390278T3 (enExample) |
| IL (1) | IL179099A (enExample) |
| PL (1) | PL1758610T3 (enExample) |
| PT (1) | PT1758610E (enExample) |
| WO (1) | WO2005113001A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| ES2390278T3 (es) * | 2004-05-20 | 2012-11-08 | Zymogenetics, Inc. | Procedimientos de tratamiento del cáncer usando tratamiento con IL-21 y anticuerpos monoclonales |
| US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
| AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
| KR100902340B1 (ko) * | 2007-08-02 | 2009-06-12 | 한국생명공학연구원 | Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법 |
| US8506933B2 (en) * | 2007-11-30 | 2013-08-13 | Msdx, Inc. | Methods of detecting a neurological condition via analysis of circulating phagocytes |
| WO2011019670A1 (en) * | 2009-08-10 | 2011-02-17 | Nayak Ramesh C | Methods of detecting responses to therapies using perforin levels |
| EP2504699A1 (en) * | 2009-11-27 | 2012-10-03 | MSDX, Inc. | Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition |
| US8673309B2 (en) | 2011-02-11 | 2014-03-18 | Msdx, Inc. | Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 |
| US9447160B2 (en) * | 2012-01-19 | 2016-09-20 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| KR101453462B1 (ko) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| CA3208721A1 (en) | 2014-04-08 | 2015-10-15 | Boston Pharmaceuticals Inc. | Binding molecules specific for il-21 and uses thereof |
| KR20160120157A (ko) | 2015-04-07 | 2016-10-17 | 주식회사 메드팩토 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
| US20200016200A1 (en) * | 2016-10-03 | 2020-01-16 | Baylor College Of Medicine | Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies |
| CA3075900A1 (en) * | 2017-09-15 | 2019-03-21 | Beckman Coulter, Inc. | Flow based assays for therapeutics |
| KR102265437B1 (ko) * | 2017-11-24 | 2021-06-15 | 의료법인 성광의료재단 | Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| EP0721983A1 (en) | 1988-01-22 | 1996-07-17 | ZymoGenetics, Inc. | Methods of producing biologically active peptide dimers |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| MY136203A (en) | 1998-08-11 | 2008-08-29 | Idec Pharma Corp | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| WO2001001748A2 (en) * | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Peptide compounds that bind her2 |
| IT1311703B1 (it) | 1999-07-23 | 2002-03-19 | Sipa Spa | Impianto ad alta efficienza di soffiaggio di preforme |
| WO2001077171A2 (en) | 2000-04-05 | 2001-10-18 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
| US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| AU2002362098A1 (en) | 2001-12-07 | 2003-06-23 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| US7452535B2 (en) * | 2002-04-12 | 2008-11-18 | Medarex, Inc. | Methods of treatment using CTLA-4 antibodies |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| ES2381265T3 (es) * | 2002-06-07 | 2012-05-24 | Zymogenetics, Inc. | Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos |
| KR20050065587A (ko) * | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| US20070092485A1 (en) * | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| PL209009B1 (pl) * | 2002-12-13 | 2011-07-29 | Zymogenetics Inc | Wektor ekspresyjny do otrzymywania białka IL-21, komórka prokariotycznego gospodarza i sposób otrzymywania białek |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| MXPA06004199A (es) * | 2003-10-17 | 2006-06-28 | Novo Nordisk As | Terapia en combinacion. |
| ES2390278T3 (es) * | 2004-05-20 | 2012-11-08 | Zymogenetics, Inc. | Procedimientos de tratamiento del cáncer usando tratamiento con IL-21 y anticuerpos monoclonales |
| LT1814580T (lt) * | 2004-11-24 | 2016-12-12 | Fred Hutchinson Cancer Research Center | Il 21 naudojimo pritaikomajai imunoterapijai ir naviko antigenų identifikavimo metodai |
-
2005
- 2005-05-20 ES ES05756320T patent/ES2390278T3/es not_active Expired - Lifetime
- 2005-05-20 BR BRPI0511187-0A patent/BRPI0511187A/pt not_active IP Right Cessation
- 2005-05-20 DK DK05756320.7T patent/DK1758610T3/da active
- 2005-05-20 PT PT05756320T patent/PT1758610E/pt unknown
- 2005-05-20 KR KR1020067026277A patent/KR101236177B1/ko not_active Expired - Fee Related
- 2005-05-20 EP EP11184743A patent/EP2431050A1/en not_active Withdrawn
- 2005-05-20 WO PCT/US2005/019126 patent/WO2005113001A1/en not_active Ceased
- 2005-05-20 CN CN2013100575165A patent/CN103127502A/zh active Pending
- 2005-05-20 CA CA002566745A patent/CA2566745A1/en not_active Abandoned
- 2005-05-20 CN CN2011101079712A patent/CN102188704B/zh not_active Expired - Fee Related
- 2005-05-20 EP EP11184521A patent/EP2425847A1/en not_active Withdrawn
- 2005-05-20 EP EP11184922A patent/EP2428216A3/en not_active Withdrawn
- 2005-05-20 EP EP05756320A patent/EP1758610B1/en not_active Expired - Lifetime
- 2005-05-20 PL PL05756320T patent/PL1758610T3/pl unknown
- 2005-05-20 AU AU2005245031A patent/AU2005245031B2/en not_active Ceased
- 2005-05-20 JP JP2007527588A patent/JP4982373B2/ja not_active Expired - Fee Related
- 2005-05-20 US US11/134,489 patent/US20050265966A1/en not_active Abandoned
-
2006
- 2006-10-06 US US11/539,493 patent/US20070122382A1/en not_active Abandoned
- 2006-10-06 US US11/539,479 patent/US20070048264A1/en not_active Abandoned
- 2006-10-06 US US11/539,511 patent/US20070178063A1/en not_active Abandoned
- 2006-11-07 IL IL179099A patent/IL179099A/en not_active IP Right Cessation
-
2008
- 2008-10-14 US US12/250,911 patent/US20090087404A1/en not_active Abandoned
-
2009
- 2009-05-19 US US12/468,516 patent/US20090269304A1/en not_active Abandoned
-
2010
- 2010-06-29 US US12/826,099 patent/US20110300098A1/en not_active Abandoned
- 2010-11-17 US US12/947,957 patent/US20110086004A1/en not_active Abandoned
-
2011
- 2011-12-27 JP JP2011284589A patent/JP2012102122A/ja not_active Ceased
-
2012
- 2012-09-28 CY CY20121100888T patent/CY1113287T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012102122A5 (enExample) | ||
| JP7106594B2 (ja) | Ｐｄ－ｌ１に対するヒト抗体 | |
| JP2014533279A5 (enExample) | ||
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| JP2016520082A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2009519257A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| CN104684552B (zh) | 组合及其用途 | |
| JP2011046732A5 (enExample) | ||
| JP2012121878A5 (enExample) | ||
| JP2011103891A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2013538796A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2013518912A5 (enExample) | ||
| JP2015521607A5 (enExample) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| JP2014502955A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| JP2009533367A5 (enExample) | ||
| JP2010500370A5 (enExample) | ||
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 |